Unknown

Dataset Information

0

Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study

ABSTRACT:

SUBMITTER: Posado-Dominguez L 

PROVIDER: S-EPMC12337030 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.
| S-EPMC11977656 | biostudies-literature
Unknown TTF-1 expression stratifies chemoimmunotherapy benefits in PD-L1-negative lung adenocarcinoma: a real-world biomarker validation
| S-EPMC12340273 | biostudies-literature
Unknown Metastatic organ count stratifies survival in immunotherapy-treated metastatic colorectal cancer: a retrospective cohort study.
| S-EPMC12723019 | biostudies-literature
Unknown Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.
| S-EPMC11929838 | biostudies-literature
Unknown FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.
| S-EPMC5503612 | biostudies-literature
Unknown Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer.
| S-EPMC10277982 | biostudies-literature
Unknown Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.
| S-EPMC9446234 | biostudies-literature
Unknown PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
| S-EPMC10642060 | biostudies-literature
Unknown Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective study.
| S-EPMC11988219 | biostudies-literature
Unknown Efficacy of chemo-immunotherapy in metastatic <i>BRAF</i>-mutated lung cancer: a single-center retrospective data.
| S-EPMC10865094 | biostudies-literature